ClinicalTrials.gg
CompletedNCT02490488Updated Dec 8, 2020

Masitinib in Combination With Gemcitabine in Advanced/Metastatic Epithelial Ovarian Cancer Patients

A Phase 2/3 interventional study of Masitinib and Gemcitabine in Ovarian Cancer, sponsored by AB Science. Completed at 6 sites in 6 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-08.

Sponsored by AB Science · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Apr 2014, registered May 2015).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
248
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Study summary

The objective is to evaluate the efficacy and safety of masitinib in combination with gemcitabine in refractory ovarian cancer patients.

Read the detailed description

Masitinib is a selective tyrosine kinase inhibitor that is thought to promote survival via modulation of immunostimulation-mediated anticancer effects and modulation of the tumor microenvironment. The objective of this study is to evaluate the efficacy and safety of masitinib in combination with gemcitabine as compared with single agent gemcitabine in advanced or metastatic epithelial ovarian cancer patients who are refractory to platinum treatment. This is an open-label, randomized, active-controlled, phase 2/3 study. The study's primary efficacy measure will be overall survival. Masitinib will be prescribed until disease progression (or treatment switch to next line of treatment), death, limiting toxicity or patient consent withdrawal. The study design is a two-stage adaptive design, meaning that it includes a prospectively planned opportunity for modification of one or more specified aspects of the study (for example patient enrollment).

02

Conditions studied

  • Ovarian Cancer

Browse trials for

Keywords

  • ovarian cancer
  • tyrosine kinase inhibitor
03

In context

Ovarian Neoplasms

3,387 studies on the registry are indexed under Ovarian Neoplasms; 792 are open to participants now.

This study's enrollment of 248 is above the median of 54 across 2,552 interventional studies indexed under Ovarian Neoplasms.

Browse Ovarian Neoplasms studies →

Lead sponsor

AB Science is the lead sponsor of 39 studies on the registry; 5 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Eligibility criteria

Main inclusion criteria:

  1. Female patient, with or cytologically confirmed advanced / epithelial ovarian cancer (including primary peritoneal and primary fallopian tube cancer), which is either:

    • platinum- ovarian cancer (progression during first-line platinum-based chemotherapy)
    • First line platinum-resistant ovarian cancer (relapsing within 6 months after the end of first-line chemotherapy);
    • Candidate to third line of treatment (refractory, resistant, or sensitive to 2nd line platinum-based therapy or patients who progressed after other type of chemotherapy in 2nd line).
  2. Patient with adequate organ function per laboratory tests evaluations

Main exclusion criteria:

  1. Patient intolerant to gemcitabine
  2. Patient who has not recovered from any significant treatment toxicities prior to baseline (≥Grade 2)
  3. Pregnant or nursing female patient
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
248 participants (actual)

Study arms

  • Experimental
    Masitinib & gemcitabine

    Participants receive masitinib (6 mg/kg/day), given orally twice daily, plus gemcitabine 1000 mg/m² administered by 30 minutes infusion once a week during 3 weeks followed by 1 week without infusion.

    Drug: Masitinib · Drug: Gemcitabine

  • Placebo comparator
    Placebo & gemcitabine

    Participants receive placebo (6 mg/kg/day), given orally twice daily, plus gemcitabine 1000 mg/m² administered by 30 minutes infusion once a week during 3 weeks followed by 1 week without infusion.

    Drug: Gemcitabine · Drug: Placebo

Interventions

  • Also known as: AB1010

  • Also known as: Gemzar

  • DrugPlacebo

    Also known as: Placebo Oral Tablet

06

What researchers measure

Primary outcomes

  1. Overall survival (OS)

    Overall survival is defined as time in months from the randomization date to the date of death due to any cause. If a patient is not known to have died, then OS will be censored at the date of last known date patient alive.

    Time frame: From day of randomization to death, assessed for a maximum of 60 months

Secondary outcomes

  1. Overall Progression Free Survival (PFS)

    Progression Free Survival (PFS) \[Time Frame: From day of randomization to disease progression or death, assessed for a maximum of 60 months\] Progression Free Survival is defined as the time from the randomization date until the date of earliest evidence of disease progression or death, for participants who progressed or died before subsequent cancer therapy. Disease progression will be assessed by CT scan according to RECIST criteria recommendations.

    Time frame: From day of randomization to disease progression or death, assessed for a maximum of 60 months

07

Study locations

6 sites
  • Centre hospitalo-universitaire de Beni Messous
    Algiers, 16340, Algeria
  • Institut Sainte Catherine
    Avignon, 84000, France
  • City Oncology Clinic
    St.-Petersburg, 198255, Russian Federation
  • Complejo Hospitalario Universitario de Santiago
    Santiago, 15706, Spain
  • Lviv State Oncological Regional Treatment and Diagnostic Center
    Lviv, 79031, Ukraine
  • University Hospital Coventry
    Coventry, CV2 2DX, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2014 to primary completion in Dec 2020, 80 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2015
First posted
Jul 3, 2015
StartActual
Apr 2014
Primary completionActual
Dec 2020
CompletionActual
Dec 2020
Results delay requested
Dec 7, 2020
Last update
Dec 8, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02490488
Lead sponsor
AB Science
Responsible party
Sponsor
First posted
Jul 3, 2015
Start date
Apr 2014
Primary completion
Dec 2020
Completion
Dec 2020
Last update
Dec 8, 2020

Study contacts

Julien Grenier, Dr
principal investigator · AB Science

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Masitinib

Start the discussion